Date: 2017-12-14
Type of information: Collaboration agreement
Compound:
Company: Samsung Medical Center (Republic of Korea) A*STAR’s Genome Institute of Singapore (GIS) (Singapore) Institute of Molecular and Cell Biology (IMCB) (Singapore) National Cancer Centre Singapore (NCCS) (Singapore) National University of Singapore (NUS) (Singapore)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration - research
Action mechanism:
Disease: hepatocellular carcinoma
Details:
- • On December 14, 2017, A*STAR’s Genome Institute of Singapore (GIS) and Institute of Molecular and Cell Biology (IMCB), National Cancer Centre Singapore (NCCS), and National University of Singapore (NUS) announced that they have concluded a collaboration with Samsung Medical Center to improve treatment of hepatocellular carcinoma. The new platform will provide reliable and robust patient-specific diagnostic and predictive data in a clinically relevant timeframe of three weeks versus the typical three to four months. Patient-derived HCC tumour samples will contribute to genomic integration, in vivo model studies and drug screening data. It will be validated to deliver precision analysis and revolutionise liver cancer treatment to improve patient outcomes.
- Professor Pierce Chow is the Lead Principal Investigator of this initiative. Professor Chow is also Surgical Director of the Comprehensive Liver Cancer Clinic at NCCS, a Professor and Course Director at the Duke-NUS Medical School, and an Associate Faculty Member at GIS.
- The collaboration leverages the strengths of current programmes in both countries – mainly the Translational and Clinical Research (TCR) Flagship Programme for Liver Cancer in Singapore, and the Refractory Cancer Research Programme of SMC, called AVATAR platform, in the Republic of Korea.
- The TCR Flagship Programme which has uncovered useful drug targets that provide critical data for drug development and precision medicine, will combine the expertise of other programmes at the Cancer Science Institute of Singapore (CSI Singapore), GIS and IMCB to re-position the AVATAR platform developed at SMC for disease areas ranging from brain cancer to HCC.
- The team aims to set up a joint lab with SMC that is based in Singapore and commence research collaborations with industry for drug development within two years.
Financial terms:
Latest news:
Is general: Yes
